Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – China In-Depth – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
The launch of several novel therapies, as well as multiple label expansions of existing drugs, will fuel significant growth of the NHL therapy market in China over the next 10 years. Rituximab (Roche’s MabThera, biosimilars) will continue to dominate the market owing to its established position in the treatment paradigm. Other key therapies expected to boost the market include CAR T-cell therapies, BTK inhibitors, bispecific antibodies, and EZH2 inhibitors. Combinations comprising Imbruvica (Johnson & Johnson Innovative Medicine / AbbVie), Calquence (AstraZeneca), and Venclexta (AbbVie / Roche) will enter the CLL segment, resulting in a shift from conventional chemotherapy and rituximab-based regimens. This report provides a comprehensive analysis of NHL patient populations, current disease management, lingering unmet needs, and the clinical and commercial potential of current and emerging drugs.
Questions answered
- How large is China’s drug-treatable NHL population, and how will drug-treatment rates change during the forecast period?
- What are interviewed experts’ insights into current treatments?
- What are the key unmet needs in the management of NHL?
- What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
Content highlights
Release date: December 2024
Geography: China
Primary research:
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 hematologist-oncologists.
Epidemiology: Diagnosed incidence of non-Hodgkin’s lymphoma in urban versus rural China, clinically relevant and market-relevant drug-treatable populations.
Forecast: 10-year, annualized,drug-level sales and patient share of key NHL therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase 3 / PR: 10+ drugs
Product description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
NEW: China In-Depth reports include a custom drug modeler. This tool enables clients to input their own assumptions for a drug and forecast three scenarios that can be directly compared with Clarivate’s projections for drugs included in the patient-based market forecast. To access the tool, download the Market Forecast Dashboard file on the Insights Platform.
